(Q44120226)

30 November 2017

title

Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry (English)

1 reference

30 November 2017

1 reference

1 reference

lymphoblastic leukemia

1 reference

17

Martin Schrappe

1 reference

30 November 2017

9

Drorit Luria

1 reference

30 November 2017

18

Jan Trka

1 reference

30 November 2017

Ester Mejstríková

1

1 reference

30 November 2017

Eva Fronková

2

1 reference

30 November 2017

Tomás Kalina

3

1 reference

30 November 2017

Marek Omelka

4

1 reference

30 November 2017

Drago Batinić

5

1 reference

30 November 2017

Klara Dubravcić

6

1 reference

30 November 2017

Klára Pospísilová

7

1 reference

30 November 2017

Martina Vásková

8

1 reference

30 November 2017

Suk Hang Cheng

10

1 reference

30 November 2017

Margaret Ng

11

1 reference

30 November 2017

Yonna Leung

12

1 reference

30 November 2017

Janos Kappelmayer

13

1 reference

30 November 2017

Flora Kiss

14

1 reference

30 November 2017

Shai Izraeli

15

1 reference

30 November 2017

Batia Stark

16

1 reference

30 November 2017

Jan Starý

19

1 reference

30 November 2017

Ondrej Hrusák

20

1 reference

30 November 2017

publication date

1 January 2010

1 reference

30 November 2017

published in

Pediatric Blood Cancer

1 reference

30 November 2017

volume

54

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

62-70

1 reference

Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction

30 November 2017

cites work

1 reference

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

21 January 2018

1 reference

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.

21 January 2018

1 reference

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital

21 January 2018

1 reference

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome

21 January 2018

1 reference

A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

21 January 2018

1 reference

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

21 January 2018

1 reference

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

21 January 2018

1 reference

Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting

21 January 2018

1 reference

CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens

21 January 2018

1 reference

CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.

21 January 2018

1 reference

Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study

21 January 2018

1 reference

Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.

21 January 2018

1 reference

Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?

21 January 2018

1 reference

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leu

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.22261

1 reference

30 November 2017

1 reference